Immunological aspects of the Guillain-Barré syndrome.
D000437:Alcoholism / Q000276:immunology; D000818:Animals; D000941:Antigens; D001500:BCG Vaccine; D002464:Cell Migration Inhibition; D002493:Central Nervous System Diseases / Q000276:immunology; D002561:Cerebrovascular Disorders / Q000276:immunology; D004586:Electrophoresis; D006168:Guinea Pigs; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008214:Lymphocytes / Q000276:immunology*; D008264:Macrophages; D009103:Multiple Sclerosis / Q000276:immunology; D009157:Myasthenia Gravis / Q000276:immunology; D009461:Neurologic Manifestations; D010523:Peripheral Nervous System Diseases / Q000276:immunology; D011128:Polyradiculopathy / Q000188:drug therapy / Q000276:immunology*; D011817:Rabbits; D012507:Sarcoidosis / Q000276:immunology; D013256:Steroids / Q000627:therapeutic use
D000941:Antigens; D001500:BCG Vaccine; D007166:Immunosuppressive Agents; D013256:Steroids